STOCK TITAN
  1. Home
  2. Sec-filings
  3. TWST
  4. [Form 4] Twist Bioscience Corp Insider Trading Activity

Twist Bioscience CEO sells 356K shares in plan

Twist Bioscience Corp (TWST) reported that Chief Executive Officer and director Emily M. Leproust exercised employee stock options and sold common shares on September 17, 2026 under a Rule 10b5-1 trading plan adopted on June 15, 2026.

Filing Impact
(Very High)
Filing Sentiment
(Very Negative)
Form Type
4

Rhea-AI Filing Summary

Twist Bioscience Corp (TWST) reported that Chief Executive Officer and director Emily M. Leproust exercised employee stock options and sold common shares on September 17, 2026 under a Rule 10b5-1 trading plan adopted on June 15, 2026.

She exercised options for 208,708 shares of Common Stock, including 75,439 shares at an exercise price of $8.82 per share expiring September 28, 2027 and 133,269 shares at an exercise price of $26.66 per share expiring November 18, 2028. On the same date she sold 356,546 shares of Common Stock in multiple open-market transactions at weighted average prices per share ranging from approximately $150.77 to $163.60.

Following these transactions, she continues to hold employee stock options directly, including options linked to 131,290 underlying shares at an exercise price of $23.33 per share expiring October 23, 2029 and options linked to 64,950 underlying shares at an exercise price of $67.85 per share expiring August 31, 2030, as reported.

Positive

  • None.

Negative

  • None.

Insights

Analyzing...

Insider Leproust Emily M.
Role Chief Executive Officer
Sold 356,546 shs ($56.33M)
Approx. gross sale proceeds $56.33M
Approx. exercise cost $4.22M
Type Security Shares Price Value
Exercise Employee Stock Option (right to buy) F18 75,439 $0.00 $0.00
Exercise Employee Stock Option (right to buy) F19 133,269 $0.00 $0.00
Exercise Common Stock F1 133,269 $26.66 $3.55M
Exercise Common Stock F1 75,439 $8.82 $665K
Sale Common Stock F1, F2 2,440 $151.4613 $370K
Sale Common Stock F1, F3 6,644 $152.2112 $1.01M
Sale Common Stock F1, F4 3,399 $153.4031 $521K
Sale Common Stock F1, F5 4,175 $154.1703 $644K
Sale Common Stock F1, F6 13,378 $155.4568 $2.08M
Sale Common Stock F1, F7 9,097 $156.4674 $1.42M
Sale Common Stock F1, F8 32,260 $157.486 $5.08M
Sale Common Stock F1, F9 232,173 $158.0876 $36.70M
Sale Common Stock F1, F10 23,884 $159.5315 $3.81M
Sale Common Stock F1, F11 14,493 $160.4392 $2.33M
Sale Common Stock F1, F12 11,169 $161.493 $1.80M
Sale Common Stock F1, F13 2,565 $162.3136 $416K
Sale Common Stock F1, F14 869 $163.3926 $142K
holding Employee Stock Option (right to buy) F15 -- -- --
holding Employee Stock Option (right to buy) F16 -- -- --
holding Employee Stock Option (right to buy) F17 -- -- --
Holdings After Transaction: Employee Stock Option (right to buy) — 196,240 contracts (Direct); Common Stock — 620,589 shares (Direct)
Footnotes (19)
  1. F1. The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 15, 2026.
  2. F2. Represents the weighted average sales price per share. The shares sold at prices ranging from $150.77 to 151.77 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
  3. F3. Represents the weighted average sales price per share. The shares sold at prices ranging from $151.78 to $152.71 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
  4. F4. Represents the weighted average sales price per share. The shares sold at prices ranging from $152.87 to $153.85 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
  5. F5. Represents the weighted average sales price per share. The shares sold at prices ranging from $153.88 to $154.84 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
  6. F6. Represents the weighted average sales price per share. The shares sold at prices ranging from $154.9 to $155.9 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
  7. F7. Represents the weighted average sales price per share. The shares sold at prices ranging from $155.92 to $156.91 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
  8. F8. Represents the weighted average sales price per share. The shares sold at prices ranging from $156.96 to $157.96 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
  9. F9. Represents the weighted average sales price per share. The shares sold at prices ranging from $157.97 to $158.96 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
  10. F10. Represents the weighted average sales price per share. The shares sold at prices ranging from $158.99 to $159.99 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
  11. F11. Represents the weighted average sales price per share. The shares sold at prices ranging from $160.00 to $160.99 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
  12. F12. Represents the weighted average sales price per share. The shares sold at prices ranging from $161.00 to $161.97 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
  13. F13. Represents the weighted average sales price per share. The shares sold at prices ranging from $162.02 to $163 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
  14. F14. Represents the weighted average sales price per share. The shares sold at prices ranging from $163.03 to $163.6 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
  15. F15. The option is immediately exercisable. 25% of the shares subject to the option vested on September 1, 2016 and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.
  16. F16. 25% of the shares subject to the option vested on October 24, 2020, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.
  17. F17. Represents performance stock options granted to the reporting person on September 1, 2020, that vested and became exercisable on December 19, 2022 as a result of the reporting person having met the applicable performance criteria.
  18. F18. The option is immediately exercisable. 10% of the shares subject to the option vested on September 28, 2017, 15% of the shares subject to the option vested on September 28, 2018, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.
  19. F19. The option is immediately exercisable. 20% of the shares subject to the option vested and became exercisable on October 31, 2019 and 1/60th of the shares subject to the option vested and became exercisable on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.
Options Exercised into Common Stock 208,708 shares Employee stock option exercises by the CEO on September 17, 2026
Shares Sold 356,546 shares Common stock sales by the CEO on September 17, 2026
Option Exercise Price $8.82 per share 75,439-share employee stock option expiring September 28, 2027
Option Exercise Price $26.66 per share 133,269-share employee stock option expiring November 18, 2028
Sale Price Range (Lower End) $150.77 per share Lower bound of reported price range for one sale bucket
Sale Price Range (Upper End) $163.60 per share Upper bound of reported price range for one sale bucket
Remaining Option Exercise Price $23.33 per share Employee stock option linked to 131,290 underlying shares expiring October 23, 2029
Remaining Option Exercise Price $67.85 per share Employee stock option linked to 64,950 underlying shares expiring August 31, 2030
Rule 10b5-1 trading plan regulatory
"transactions were effected pursuant to a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average sales price per share financial
"Represents the weighted average sales price per share."
performance stock options financial
"Represents performance stock options granted to the reporting person"
underlying shares financial
"underlying shares 131,290.0000 of Common Stock"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did TWST’s CEO Emily Leproust do in this Form 4 filing?
She exercised employee stock options for 208,708 shares of Twist Bioscience common stock and sold 356,546 shares in multiple open-market transactions on September 17, 2026, all under a previously adopted Rule 10b5-1 trading plan.

How many TWST options did the CEO exercise and at what prices?
She exercised options for 208,708 shares, including 75,439 shares at $8.82 per share (expiring September 28, 2027) and 133,269 shares at $26.66 per share (expiring November 18, 2028), receiving the underlying common stock as reported.

How many TWST shares did the CEO sell and at what price range?
She sold 356,546 shares of Twist Bioscience common stock in separate open-market transactions at weighted average prices per share within ranges from about $150.77 to $163.60, according to the reported trade buckets and related footnotes.

Were the TWST trades by the CEO made under a Rule 10b5-1 plan?
Yes. The filing states the transactions were effected pursuant to a Rule 10b5-1 trading plan previously adopted by Emily Leproust on June 15, 2026, indicating the trades were pre-arranged under that plan.

What TWST stock options does the CEO still hold after these transactions?
She continues to hold employee stock options directly, including options linked to 131,290 underlying shares at $23.33 per share expiring October 23, 2029 and options linked to 64,950 underlying shares at $67.85 per share expiring August 31, 2030, as reported.

What is the significance of the weighted average prices reported for TWST share sales?
Each sale line shows a weighted average sales price per share, with footnotes explaining that the underlying trades occurred in price ranges (for example, $150.77–$151.77), and detailed per-trade information is available on request to regulators, the issuer, or security holders.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Leproust Emily M.
(Last)(First)(Middle)
C/O TWIST BIOSCIENCE CORPORATION
681 GATEWAY BLVD.
(Street)
SOUTH SAN FRANCISCO CALIFORNIA 94080
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Twist Bioscience Corp [ TWST ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
Chief Executive Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
09/17/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock09/17/2026M(1)133,269A$26.66901,696D
Common Stock09/17/2026M(1)75,439A$8.82977,135D
Common Stock09/17/2026S(1)2,440D$151.4613(2)974,695D
Common Stock09/17/2026S(1)6,644D$152.2112(3)968,051D
Common Stock09/17/2026S(1)3,399D$153.4031(4)964,652D
Common Stock09/17/2026S(1)4,175D$154.1703(5)960,477D
Common Stock09/17/2026S(1)13,378D$155.4568(6)947,099D
Common Stock09/17/2026S(1)9,097D$156.4674(7)938,002D
Common Stock09/17/2026S(1)32,260D$157.486(8)905,742D
Common Stock09/17/2026S(1)232,173D$158.0876(9)673,569D
Common Stock09/17/2026S(1)23,884D$159.5315(10)649,685D
Common Stock09/17/2026S(1)14,493D$160.4392(11)635,192D
Common Stock09/17/2026S(1)11,169D$161.493(12)624,023D
Common Stock09/17/2026S(1)2,565D$162.3136(13)621,458D
Common Stock09/17/2026S(1)869D$163.3926(14)620,589D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Employee Stock Option (right to buy)$5.95 (15)09/28/2025Common Stock00D
Employee Stock Option (right to buy)$23.33 (16)10/23/2029Common Stock131,290131,290D
Employee Stock Option (right to buy)$67.8512/19/202208/31/2030Common Stock64,95064,950(17)D
Employee Stock Option (right to buy)$8.8209/17/2026M75,439 (18)09/28/2027Common Stock75,439$00D
Employee Stock Option (right to buy)$26.6609/17/2026M133,269 (19)11/18/2028Common Stock133,269$00D
Explanation of Responses:
1. The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 15, 2026.
2. Represents the weighted average sales price per share. The shares sold at prices ranging from $150.77 to 151.77 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
3. Represents the weighted average sales price per share. The shares sold at prices ranging from $151.78 to $152.71 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
4. Represents the weighted average sales price per share. The shares sold at prices ranging from $152.87 to $153.85 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
5. Represents the weighted average sales price per share. The shares sold at prices ranging from $153.88 to $154.84 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
6. Represents the weighted average sales price per share. The shares sold at prices ranging from $154.9 to $155.9 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
7. Represents the weighted average sales price per share. The shares sold at prices ranging from $155.92 to $156.91 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
8. Represents the weighted average sales price per share. The shares sold at prices ranging from $156.96 to $157.96 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
9. Represents the weighted average sales price per share. The shares sold at prices ranging from $157.97 to $158.96 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
10. Represents the weighted average sales price per share. The shares sold at prices ranging from $158.99 to $159.99 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
11. Represents the weighted average sales price per share. The shares sold at prices ranging from $160.00 to $160.99 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
12. Represents the weighted average sales price per share. The shares sold at prices ranging from $161.00 to $161.97 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
13. Represents the weighted average sales price per share. The shares sold at prices ranging from $162.02 to $163 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
14. Represents the weighted average sales price per share. The shares sold at prices ranging from $163.03 to $163.6 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
15. The option is immediately exercisable. 25% of the shares subject to the option vested on September 1, 2016 and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.
16. 25% of the shares subject to the option vested on October 24, 2020, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.
17. Represents performance stock options granted to the reporting person on September 1, 2020, that vested and became exercisable on December 19, 2022 as a result of the reporting person having met the applicable performance criteria.
18. The option is immediately exercisable. 10% of the shares subject to the option vested on September 28, 2017, 15% of the shares subject to the option vested on September 28, 2018, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.
19. The option is immediately exercisable. 20% of the shares subject to the option vested and became exercisable on October 31, 2019 and 1/60th of the shares subject to the option vested and became exercisable on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.
Remarks:
/s/ Kendra Fox, as Attorney-in-Fact for Emily M. Leproust09/21/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

Keep reading

More on TWST

Trending in the feed

Open the live feed